Pfizer to replace migraine drug Nurtec ODT packaging over child safety concerns

As an interim measure, the company has instructed pharmacists to place the drug packet in a child-resistant vial before dispensing it to patients.

Published On 2023-03-18 05:30 GMT   |   Update On 2023-03-18 05:30 GMT

New York: Pfizer Inc said on Thursday it was working on a new child-proof packaging for its migraine drug, Nurtec ODT, after safety concerns led to a recall alert from the U.S. Consumer Product Safety Commission (CPSC).Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child-resistant pouch to store it, the CPSC...

Login or Register to read the full article

New York: Pfizer Inc said on Thursday it was working on a new child-proof packaging for its migraine drug, Nurtec ODT, after safety concerns led to a recall alert from the U.S. Consumer Product Safety Commission (CPSC).

Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child-resistant pouch to store it, the CPSC said.

The CPSC defines recalls as any repair, replacement, refund, or warning.

Pfizer said it was developing a new packaging for the drug acquired through its $11.6 billion buyout of Biohaven Pharmaceutical Holding in 2022.

As an interim measure, the company has instructed pharmacists to place the drug packet in a child-resistant vial before dispensing it to patients.

Read also: Glenmark Pharma bags USFDA nod for generic version of Cleocin Hydrochloride Capsules

"Patients should rest assured that there are no quality or safety issues nor health risks when they take the medicine as prescribed for its approved use," the company said in a statement.

The orally disintegrating tablets are used for the treatment of acute migraine and as preventive treatment for episodic migraine in adults

Read also: Pfizer bags USFDA nod for migraine nasal spray ZAVZPRET



Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News